Predicting Successful Conservative Surgery after Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to determine whether clinicopathological factors are potentially associated with successful breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) and develop a nomogram for predicting successful BCS candidates, focusing on those who are diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative tumors during the pre- NAC period. Methods: The training cohort included 239 patients with an HR-positive, HER2-negative tumor (≥3 cm), and all of these patients had received NAC. Patients were excluded if they met any of the following criteria: diffuse, suspicious, malignant microcalcification (extent >4 cm); multicentric or multifocal breast cancer; inflammatory breast cancer; distant metastases at the time of diagnosis; excisional biopsy prior to NAC; and bilateral breast cancer. Multivariate logistic regression analysis was conducted to evaluate the possible predictors of BCS eligibility after NAC, and the regression model was used to develop the predicting nomogram. This nomogram was built using the training cohort (n=239) and was later validated with an independent validation cohort (n=123). Results: Small tumor size (p<0.001) at initial diagnosis, long distance from the nipple (p=0.002), high body mass index (p=0.001), and weak positivity for progesterone receptor (p=0.037) were found to be four independent predictors of an increased probability of BCS after NAC; further, these variables were used as covariates in developing the nomogram. For the training and validation cohorts, the areas under the receiver operating characteristic curve were 0.833 and 0.786, respectively; these values demonstrate the potential predictive power of this nomogram. Conclusion: This study established a new nomogram to predict successful BCS in patients with HR-positive, HER2-negative breast cancer. Given that chemotherapy is an option with unreliable outcomes for this subtype, this nomogram may be used to select patients for NAC followed by successful BCS.
Abstract
Purpose: This study aimed to determine whether clinicopathological factors are potentially associated with successful breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) and develop a nomogram for predicting successful BCS candidates, focusing on those who are diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative tumors during the pre- NAC period. Methods: The training cohort included 239 patients with an HR-positive, HER2-negative tumor (≥3 cm), and all of these patients had received NAC. Patients were excluded if they met any of the following criteria: diffuse, suspicious, malignant microcalcification (extent >4 cm); multicentric or multifocal breast cancer; inflammatory breast cancer; distant metastases at the time of diagnosis; excisional biopsy prior to NAC; and bilateral breast cancer. Multivariate logistic regression analysis was conducted to evaluate the possible predictors of BCS eligibility after NAC, and the regression model was used to develop the predicting nomogram. This nomogram was built using the training cohort (n=239) and was later validated with an independent validation cohort (n=123). Results: Small tumor size (p<0.001) at initial diagnosis, long distance from the nipple (p=0.002), high body mass index (p=0.001), and weak positivity for progesterone receptor (p=0.037) were found to be four independent predictors of an increased probability of BCS after NAC; further, these variables were used as covariates in developing the nomogram. For the training and validation cohorts, the areas under the receiver operating characteristic curve were 0.833 and 0.786, respectively; these values demonstrate the potential predictive power of this nomogram. Conclusion: This study established a new nomogram to predict successful BCS in patients with HR-positive, HER2-negative breast cancer. Given that chemotherapy is an option with unreliable outcomes for this subtype, this nomogram may be used to select patients for NAC followed by successful BCS.
참고문헌 (18)
- Sinclair S, "Primary systemic chemotherapy for inflammatory breast cancer", Cancer, 116(11 Suppl), pp.2821~2828 (2010)
- Specht J, "Neoadjuvant chemotherapy for locally advanced breast cancer", Semin Radiat Oncol, 19, pp.222~228 (2009)
- Rouzier R, "Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer", Cancer, 107, pp.1459~1466 (2006)
- 김민균, "Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy", Cancer Research and Treatment, 47(2), pp.197~207 (2015), 대한암학회[DOI]
- Boughey JC, "Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial", Ann Surg, 260, pp.608~614 (2014)
- Killelea BK, "Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database", J Am Coll Surg, 220, pp.1063~1069 (2015)
- Albain KS, "Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial", Lancet Oncol, 11, pp.55~65 (2010)
- Martin M, "Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+", HER2- breast cancer patients: results from the GEICAM 9906 trial, 2014, pp.16, R38~
- Cardoso F, "70-Gene signature as an aid to treatment decisions in early-stage breast cancer", N Engl J Med, 375, pp.717~729 (2016)
- Harvey JM, "Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer", J Clin Oncol, 17, pp.1474~1481 (1999)
- Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2014, pp.138, 241~256
- Mathieu MC, "Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy", Ann Oncol, 23, pp.2046~2052 (2012)
- Hage AN, "Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer", J Surg Oncol, 116, pp.665~670 (2017)
- Simmons RM, "Recurrence rates in patients with central or retroareolar breast cancers treated with mastectomy or lumpectomy", Am J Surg, 182, pp.325~329 (2001)
- 임라주, "중심부 유방암에서 중심 종양절제술의 의의", Annals of Surgical Treatment and Research, 79(4), pp.275~280 (2010), 대한외과학회
- Coltman CE, "Breast volume is affected by body mass index but not age", Ergonomics, 60, pp.1576~1585 (2017)
- Katariya RN, "Breast volumes in cancer of the breast", Br J Cancer, 29, pp.270~273 (1974)
- Warner ET, "Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)", Breast Cancer Res Treat, 159, pp.109~118 (2016)